Joint salvage for pathologic fracture of giant cell tumor of the lower extremity.

Autor: Deheshi BM; University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada., Jaffer SN, Griffin AM, Ferguson PC, Bell RS, Wunder JS
Jazyk: angličtina
Zdroj: Clinical orthopaedics and related research [Clin Orthop Relat Res] 2007 Jun; Vol. 459, pp. 96-104.
DOI: 10.1097/BLO.0b013e31805d85e4
Abstrakt: Pathologic fracture through giant cell tumor is thought to be associated with higher rates of recurrence and poor functional outcome. We compared patients with and without pathologic fracture through giant cell tumor of weightbearing long bones. We retrospectively reviewed 139 patients with giant cell tumor of weightbearing long bones with (n = 43) and without (n = 96) pathologic fracture at presentation; the two groups had similar demographics. Joint salvage was successful in 84% of the fracture group and 96% of the nonfracture group. Five-year recurrence-free survival rates were comparable between the two groups (82.6% [95% confidence interval, 69.1-95.9%] in the fracture group and 77.9% [95% confidence interval, 67.7-88.1%] in the non-fracture group). There was a trend toward lower 5-year metastatic-free survival in the fracture group (94.7% [95% confidence interval, 87.3-100%]) than in the nonfracture group (97.3% [95% confidence interval, 93.5-100%]). Functional outcome was good and similar in the two groups. Arthrofibrosis was more common in the group with pathologic fracture. Joint salvage for patients with pathologic fractures through giant cell tumor of weightbearing bones is a reasonable option with functional outcomes and recurrence rates comparable to those of patients without fracture.
Databáze: MEDLINE